Ayahuasca is an entheogenic botanical decoction originating within the indigenous medical and spiritual traditions of the Upper Amazon Basin. By combining plants rich in N,N-dimethyltryptamine with species containing beta-carboline alkaloids, this complex brew bypasses gastrointestinal degradation to induce profound alterations in human consciousness, neurobiology, and subjective psychological functioning. In recent decades, ayahuasca has crossed indigenous boundaries to become a focal subject in neuropsychiatry, psychopharmacology, anthropology, and transpersonal psychology.
Ayahuasca
1. Concise Definition
Ayahuasca is a psychoactive botanical brew traditionally prepared by boiling the woody stems of the vine Banisteriopsis caapi together with the leaves of dimethyltryptamine-containing admixture plants, most commonly Psychotria viridis or Diplopterys cabrerana. Functioning as a synergistic pharmacological formulation, the brew facilitates profound modifications of sensory perception, emotional regulation, introspective cognition, and existential awareness.
Pharmacologically, the brew operates via a unique mechanism of dual-component synergy: the reversible inhibition of peripheral monoamine oxidase type A (MAO-A) by beta-carbolines allows orally ingested N,N-dimethyltryptamine (DMT) to enter systemic circulation and cross the blood-brain barrier. Psychologically, ayahuasca induces an acute state of modified consciousness marked by vivid visual imagery, intensified emotional catharsis, autobiographical memory retrieval, and pronounced feelings of interconnectedness or transpersonal unity.
Beyond its biochemical properties, ayahuasca represents a complex cultural, ritualistic, and therapeutic matrix. Historically utilized by indigenous Amazonian healers (vegetalistas, ayahuasqueros, and curanderos) for divination, diagnostic evaluation, and somatic-spiritual healing, the preparation has modernly expanded into syncretic religious institutions, clinical trial paradigms for treatment-resistant psychiatric conditions, and international wellness tourism networks.
2. Etymology & Linguistic Origin
The term ayahuasca derives from Quechuan linguistic roots, a major indigenous language family spoken across the Andean and western Amazonian zones of South America. The word is an agglutinative compound composed of the Quechua lexemes aya, which translates variously as “spirit,” “soul,” “ancestor,” or “corpse/dead person,” and waska (or huasca), which signifies “vine,” “rope,” or “woody cord.” Consequently, the compound is most accurately translated as “vine of the dead,” “vine of the souls,” or “rope of the spirits.”
Linguistic variations reflect the extensive geographic distribution and cultural diversity of Amazonian ethnobotany. In Portuguese-speaking regions of Brazil, the decoction is frequently referred to as cipó (vine) or daime (within the Santo Daime religious tradition, originating from the petitionary phrase dai-me amor or “give me love”), and vegetal (within the União do Vegetal). In other indigenous vernaculars across Peru, Colombia, Ecuador, and Bolivia, the brew and its primary vine are known as yagé (alternatively spelled yajé among Tukanoan and Western Tucanoan peoples such as the Siona, Secoya, and Kofán), nixi pae (among the Huni Kuin/Kaxinawá), kamalampi (among the Matsigenka), and natem (among the Shuar).
The term formally entered Western scientific nomenclature through mid-nineteenth-century botanical explorations, notably via the English botanist Richard Spruce, who documented the preparation and botanical identity of Banisteriopsis caapi during his expeditions along the Rio Negro and across the Ecuadorian and Peruvian Amazon between 1849 and 1864. Spruce collected voucher specimens and recorded the indigenous social contexts surrounding the brew’s utilization.
3. Pronunciation & Grammatical Form
In standard international English phonetic transcription, ayahuasca is pronounced /ˌaɪəˈwæskə/ or /ˌaɪəˈwɑːskə/. In Spanish phonetic systems, it is pronounced [aʝaˈwaska], whereas Portuguese speakers typically articulate it as [ajaˈwaskɐ].
Grammatically, the term functions primarily as an uncountable (mass) noun when designating the psychoactive decoction itself (e.g., “The pharmacology of ayahuasca has been examined extensively”). It may also function attributively as a noun adjunct modifying other nouns (e.g., “ayahuasca ceremony,” “ayahuasca-induced neuroplasticity,” “ayahuasca tourism”). Less frequently, the term refers metonymically to the botanical vine Banisteriopsis caapi itself, distinguishing it from the multi-plant prepared brew.
4. Detailed Conceptual Explanation
The conceptual framework of ayahuasca spans ethnobotany, psychopharmacology, clinical psychiatry, and anthropology. Fundamentally, ayahuasca cannot be understood merely as an isolated chemical substance; it is an orally active, multi-component botanical technology that produces coordinated disruptions across central neurochemical, psychological, and physiological systems.
The neuropharmacological mechanism of ayahuasca is celebrated as a paradigm of indigenous biochemical discovery. In its natural oral route, DMT is rapidly converted into the inactive metabolite indole-3-acetic acid by intestinal and hepatic monoamine oxidase type A (MAO-A), rendering oral consumption of DMT-containing foliage inert. However, the woody stems of Banisteriopsis caapi contain substantial concentrations of harmala alkaloids, primarily harmine, tetrahydroharmine (THH), and harmaline. Harmine and harmaline serve as potent, selective, and reversible inhibitors of monoamine oxidase A (RIMAs), effectively shielding DMT from visceral metabolic breakdown. Concurrently, tetrahydroharmine functions as a weak serotonin reuptake inhibitor and modest MAO inhibitor, amplifying central serotonergic transmission.
Upon crossing the blood-brain barrier, DMT acts as a high-affinity partial agonist at serotonin 5-HT2A receptors, as well as exhibiting affinity for 5-HT2C, 5-HT1A, and sigma-1 receptor sites. The agonist binding at 5-HT2A receptors, predominantly localized on cortical layer V pyramidal neurons, triggers an extensive intracellular cascade involving G-protein-coupled receptor signaling, glutamate release, and profound alterations in spontaneous neuronal firing. This biochemical cascade produces functional desynchronization within associative cortical regions, particularly downregulating the resting-state functional connectivity of the default mode network (DMN). The attenuation of DMN coherence correlates directly with the breakdown of standard narrative self-referential processing, a subjective phenomenon known as ego dissolution.
Phenomenologically, the ayahuasca experience typically begins between 30 and 60 minutes following oral ingestion, reaching peak intensity between 90 and 180 minutes, and resolving over a duration of 4 to 6 hours. The acute state encompasses both physical and psychological dimensions. Somatically, it frequently elicits nausea, emesis, diaphoresis, motor ataxia, and tremors—manifestations understood within traditional shamanic paradigms as la purga (the purge), a vital physical and energetic detoxification rather than an unwanted side effect. Psychologically, subjects experience vivid open- and closed-eye visionary phenomena, synesthesia, dramatic cognitive insights, emotional catharsis, the revivification of repressed or forgotten autobiographical memories, and ontological encounters with perceived non-ordinary entities or ancestral presences.
5. Historical Development
The chronological origin of ayahuasca utilization among Amazonian indigenous groups remains an active area of archaeological, historical, and anthropological inquiry. Direct organic material evidence of ayahuasca in ancient contexts is challenging to preserve due to tropical soil acidity and rapid degradation. However, archaeological excavations in the Lipez Altiplano of southwestern Bolivia uncovered a ritual bundle dating to approximately 1,000 CE (associated with the Tiwanaku cultural sphere) containing traces of DMT, harmine, and other psychoactive compounds, demonstrating that the chemical co-administration of these alkaloids has deep pre-Columbian antiquity in South America.
Early European historical accounts began emerging during the sixteenth and seventeenth centuries, penned by Spanish and Portuguese Jesuit missionaries and colonial chroniclers. These observers routinely demonized native plant preparations as demonic sorcery and idolatrous pagan practices, which led to clandestine ceremonial use among subjugated indigenous communities. Despite colonial persecution, vegetalismo developed as an ethnobotanical medical tradition throughout western Amazonia, synthesizing indigenous techniques with Iberian folk Catholicism, European folk magic, and African healing arts.
Scientific codification commenced in the mid-19th century with Richard Spruce’s field observations in 1851. In the early 20th century, Western chemists isolated the primary alkaloids: harmine was isolated from Peganum harmala and later identified in B. caapi (initially named telepathine by Colombian chemist Guillermo Fischer-Cárdenas in 1923 due to claims of induced telepathy, and banisterine by Louis Lewin in 1928, before chemical equivalence to harmine was established). DMT was first synthesized by Richard Manske in 1931, but its natural presence in Amazonian admixture plants (such as Psychotria viridis) and its synergistic pharmacology with harmala alkaloids were not fully clarified until the seminal ethnobotanical and chemical investigations conducted by Bo Holmstedt, Richard Evans Schultes, Laurent Rivier, and Dennis McKenna between the 1960s and 1980s.
During the 1920s and 1930s in Brazil, a parallel cultural trajectory emerged with the founding of Brazilian syncretic ayahuasca churches. Raimundo Irineu Serra founded the Santo Daime tradition in Acre, Brazil, merging vegetalismo, Spiritism (Kardecism), and popular Catholicism. In 1961, José Gabriel da Costa established the Beneficent Spiritist Center União do Vegetal (UDV). In the late 20th and early 21st centuries, these organizations secured formal legal recognition in Brazil and expanded globally, establishing branches in North America and Europe. This institutional expansion coincided with the explosion of international psychedelic tourism in Iquitos, Tarapoto, and Pucallpa (Peru), alongside the formal scientific integration of ayahuasca into clinical psychiatric research.
6. Theoretical Foundations
Understanding ayahuasca requires the integration of diverse theoretical frameworks spanning neuroscience, cognitive psychology, evolutionary biology, and sociocultural anthropology. The primary modern neuroscientific lens applied to ayahuasca is the REBUS framework (Relaxed Beliefs Under Psychedelics), developed by Robin Carhart-Harris and Karl Friston, which is rooted in predictive processing models of brain function.
Under the predictive processing architecture, the human brain functions as an active inference machine that maintains hierarchical internal models to predict incoming sensory data. Higher-level associative regions encode top-down “priors” (beliefs, expectations, identity narratives) that constrain lower-level perceptual inputs. According to the REBUS model, 5-HT2A agonist psychedelics like the DMT in ayahuasca systematically decrease the precision-weighting of high-level cortical priors. This relaxation permits bottom-up sensory information and subcortical emotional signals to flow more freely into conscious awareness. Pathological, rigid thought patterns characteristic of depression, obsessive-compulsive disorders, and addictions are temporarily disintegrated, opening a critical window of cognitive plasticity.
From a psychodynamic and transpersonal perspective, ayahuasca is theorized to function as an “affective amplifier” and “oneirogen” (dream generator). Theoretical formulations by Benny Shanon describe ayahuasca not simply as a biochemical disruptor, but as an engine of structural ideation and visual semiosis. Under this view, the brew activates deep archetypal structures, narrative myth-making, and emotional reframing. Unconscious psychological defense mechanisms, such as repression, intellectualization, and denial, become temporarily permeable, allowing patients to confront traumatic developmental memories with therapeutic detachment and self-compassion.
Anthropological and indigenous animist frameworks interpret ayahuasca through entirely different ontological commitments. Within Amazonian perspectivism, formulated theoretically by Eduardo Viveiros de Castro, the cosmos is inhabited by multiple subjective points of view; plants, animals, and spirits possess human-like interiority. Within this worldview, ayahuasca is not a drug or object, but a master plant teacher (planta maestra) endowed with agency. The decoction alters the bodily matrix of the human subject, allowing their soul to navigate invisible planes, communicate with plant and non-human intelligences, and repair imbalances caused by sorcery, interpersonal conflict, or ecological transgression.
7. Key Components, Types & Dimensions
Ayahuasca is characterized by diverse botanical preparations, biochemical active agents, and experiential dimensions, detailed as follows:
- Botanical Components:
- Primary Base Vine: Banisteriopsis caapi (family Malpighiaceae), known for its thick, woody liana stems that provide the beta-carboline enzymatic inhibitor backbone.
- Primary DMT Admixtures: Psychotria viridis (Chacruna; family Rubiaceae) in the western and southern Amazon; Diplopterys cabrerana (Chaliponga or Chagropanga; family Malpighiaceae) frequently used in Colombia and Ecuador, containing both DMT and 5-methoxy-DMT (5-MeO-DMT).
- Secondary Botanical Admixtures: Regional variations include Nicotiana rustica (Mapacho), Brugmansia species (Toé, containing tropane alkaloids), and Brunfelsia grandiflora (Chiricsanango), integrated for specific curative or visionary objectives.
- Pharmacological Alkaloids:
- N,N-Dimethyltryptamine (DMT): The main psychoactive visionary agent; an indole alkaloid acting as a partial agonist at central 5-HT2A receptors.
- Harmine: A tricyclic beta-carboline; a potent, selective, reversible inhibitor of peripheral and central MAO-A, possessing distinct anti-inflammatory and neurogenic properties.
- Tetrahydroharmine (THH): A reduced beta-carboline that provides modest monoamine oxidase inhibition while acting as a selective serotonin reuptake inhibitor (SSRI).
- Harmaline: A minor beta-carboline relative to harmine in most preparations; serves as a powerful, reversible MAO-A inhibitor.
- Contextual Typologies:
- Traditional Indigenous Shamanism: Rituals focused on physical cure, energetic hunting preparation, communal protection, and lineage-specific cosmological instruction.
- Mestizo Vegetalismo: Urban and rural syncretic healing practices incorporating folk Catholicism, perfume magic, and specialized healing songs (ícaros).
- Syncretic Religious Formations: Highly structured, doctrine-driven spiritual institutions, such as the Santo Daime, União do Vegetal (UDV), and Barquinha.
- Neo-Shamanic and Psychotherapeutic Retreats: Contemporary formats tailored toward international participants seeking personal transformation, trauma processing, and spiritual exploration.
8. Examples & Illustrative Cases
The applications and manifestations of the ayahuasca experience vary widely depending on setting, psychological state, and intent. The following illustrative scenarios demonstrate its use across disparate settings:
Case Illustration 1: Clinical Psychiatric Application. A 42-year-old patient suffering from chronic, treatment-resistant major depressive disorder participated in a controlled clinical trial evaluating the therapeutic efficacy of a standardized single dose of ayahuasca. Within 45 minutes of administration under double-blind medical supervision, the patient experienced intense autonomic arousal and emesis, followed by vivid closed-eye imagery. The patient visualized past traumatic childhood memories regarding familial estrangement, but experienced them stripped of the customary visceral terror. Instead, the narrative was viewed from a compassionate, detached perspective. Over the subsequent 21 days post-session, the patient exhibited significant drops in scores on the Montgomery-Åsberg Depression Rating Scale (MADRS), accompanied by reported increases in psychological flexibility and subjective life meaning.
Case Illustration 2: Traditional Indigenous Healing Ceremony. In an indigenous Shipibo-Konibo community along the Ucayali River in Peru, a community member suffering from chronic somatic fatigue and existential despair approached an onanya (traditional master healer). In a nighttime ceremony, both the onanya and the patient consumed ayahuasca. Rather than viewing the brew as a self-administered therapeutic agent alone, the healer relied on its visionary action to “diagnose” spiritual blockages and energetic distortions across the patient’s body. The healer sang customized ícaros directly into the crown of the patient’s head, administered tobacco smoke via mapacho blowing (soplada), and directed the visionary field toward re-establishing cosmic and bodily equilibrium.
Case Illustration 3: Syncretic Religious Context. During a formal ritual service (trabalho) of the Santo Daime church, hundreds of uniformed congregants drank measured portions of the brew (referred to as Daime). Over several hours, participants stood in organized geometric lines, performing repetitive rhythmic dances and singing Portuguese spiritual hymns accompanied by maracas. In this context, subjective visionary experiences were anchored into collective, structured religious practice, illustrating how community container and doctrine modulate the experiential trajectory of the compound.
9. Measurement & Assessment
Assessing ayahuasca in clinical, psychological, and analytical frameworks involves measuring both chemical composition and phenomenological dynamics.
From an analytical chemistry perspective, because natural plant decoctions exhibit high variability in alkaloid ratios, researchers must precisely quantify the concentrations of DMT, harmine, tetrahydroharmine, and harmaline. Standardized protocols utilize high-performance liquid chromatography (HPLC), liquid chromatography-mass spectrometry (LC-MS), or gas chromatography-mass spectrometry (GC-MS). Quality control frameworks establish standardized reference materials to deliver uniform milligram-per-kilogram doses of active alkaloids in human clinical trials.
In human clinical and neuroscientific studies, subjective changes are measured using psychometric inventories, including:
- Hallucinogen Rating Scale (HRS): Developed by Rick Strassman, this scale isolates six primary dimensions: Somaesthesia, Affect, Volition, Perception, Cognition, and Intensity.
- Mystical Experience Questionnaire (MEQ30): Quantifies transcendental components such as mystical unity, sacredness, positive mood, and ineffability.
- Ego Dissolution Inventory (EDI): Measures the acute disruption of self-boundaries and narrative identity integrity.
- 5-Dimensional Altered States of Consciousness Rating Scale (5D-ASC): Widely utilized to track visual restructuralization, oceanic boundlessness, and dread of ego dissolution.
- Acceptance and Action Questionnaire-II (AAQ-II) and Mindful Attention Awareness Scale (MAAS): Deployed longitudinally to assess enduring post-acute changes in psychological flexibility and cognitive mindfulness.
10. Applications & Practical Significance
The applications of ayahuasca encompass psychiatric therapeutics, addiction recovery, organizational and social psychology, and creative neurocognition. In modern psychopharmacology, researchers evaluate ayahuasca as a candidate intervention for psychiatric disorders characterized by cognitive rigidity, compulsive rumination, and affective blunting.
In addiction therapy, observational and preliminary clinical studies have shown positive outcomes when ayahuasca ceremonies are incorporated into addiction rehabilitation models, such as those historically conducted at the Takiwasi Center in Tarapoto, Peru. By fostering deep emotional insights, facilitating confrontation with suppressed guilt and trauma, and stimulating sustained neurobiological neuroplastic changes, ayahuasca-assisted interventions have helped individuals reduce dependence on cocaine, alcohol, and opioids.
Additionally, clinical investigations explore the brew’s potential in mitigating symptoms of post-traumatic stress disorder (PTSD). Ayahuasca appears to facilitate the reconsolidation of traumatic memories by dampening amygdaloid hyper-reactivity while simultaneously upregulating prefrontal cognitive control. In non-clinical populations, regular participants in structured settings frequently display elevated scores in trait openness, mindfulness, and subjective well-being, coupled with lower baseline indices of neuropsychiatric distress.
11. Research & Empirical Evidence
Empirical scientific interest in ayahuasca has escalated over the past three decades, transitioning from qualitative naturalistic observations to rigorous neuroimaging and randomized, placebo-controlled clinical trials.
A landmark moment in medical research occurred with the Hoasca Project in the early 1990s, spearheaded by Charles Grob, Dennis McKenna, Jace Callaway, and colleagues. This multidisciplinary study conducted comprehensive psychiatric, physiological, and biochemical evaluations of long-term members of the União do Vegetal church in Brazil. The findings indicated that regular, long-term religious consumption of ayahuasca was not associated with neuropsychological deficits; conversely, adherents showed significant remissions of past affective and substance use disorders, alongside an upregulation of platelet serotonin uptake sites.
In the domain of psychiatry, randomized controlled trials led by researchers at the Federal University of Rio Grande do Norte in Brazil (including Fernanda Palhano-Fontes, Draúzio de Araújo, and colleagues) examined the effects of a single dose of ayahuasca versus an active placebo in patients with treatment-resistant depression. Their findings confirmed rapid, statistically significant, and enduring antidepressant effects, detectable within hours of administration and maintained up to three weeks post-session, accompanied by modulation of neuroinflammatory markers such as brain-derived neurotrophic factor (BDNF).
Functional neuroimaging studies utilizing functional magnetic resonance imaging (fMRI) and single-photon emission computed tomography (SPECT) have illuminated the neural correlates of the state. Research shows marked blood perfusion changes in anterior cingulate, insular, and frontomedial cortices, alongside significant functional connectivity decreases within the default mode network. Research further documents that harmine and related alkaloids induce potent in vitro neurogenesis, stimulating the proliferation and differentiation of human neural stem cells.
12. Cultural & Cross-Cultural Considerations
Ayahuasca occupies radically different positions across varying cultural landscapes. In indigenous Amazonian societies, it is interwoven with traditional lifeways, ecological stewardship, tribal cosmologies, and healthcare. Its practice is governed by structured cultural norms: dietary restrictions (dietas), sexual abstinence, and specific master-apprentice lineages that require years of solitary immersion to master.
When transplanted into contemporary Western paradigms, tensions often arise between indigenous frameworks and clinical or commercial models. Indigenous leaders and anthropologists have expressed valid concerns regarding cultural appropriation, the commodification of sacred indigenous medicines, and the biopiracy of Amazonian genetic resources. The international expansion of ayahuasca tourism has also generated socioeconomic shifts across Amazonian cities, creating boom economies centered around retreat centers while sometimes disrupting local cultural dynamics.
Legally and culturally, countries vary significantly in how they govern the brew. In Peru, the traditional knowledge and uses of ayahuasca were officially declared a National Cultural Heritage by the National Institute of Culture in 2008. In Brazil, religious use is formally legal and protected under constitutional guarantees of religious freedom. Conversely, in many Western jurisdictions (including the United States, France, and the United Kingdom), DMT is classified as a Schedule I / Class A controlled substance, leading to protracted legal battles over religious exemptions and human rights protections under religious freedom restoration acts.
13. Criticisms, Debates & Limitations
Despite its therapeutic promise, ayahuasca administration is accompanied by critical clinical risks, contraindications, and unresolved debates:
- Psychiatric Vulnerability: The profound psychological intensity of the brew can trigger acute anxiety, psychotic episodes, or prolonged depersonalization/derealization, particularly in individuals with personal or familial histories of schizophrenia, bipolar disorder, or borderline personality organization.
- Somatic and Pharmacological Contraindications: Co-administration of ayahuasca with selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), or monoamine oxidase inhibitors presents a severe risk of precipitating lethal serotonin syndrome. Furthermore, transient increases in heart rate and blood pressure contraindicate use in patients with unstable cardiovascular conditions.
- Misconduct and Unregulated Facilitation: The unregulated international expansion of retreat centers has resulted in instances of psychological abuse, sexual assault, financial exploitation, and fatal physical neglect by unqualified practitioners or charlatans presenting as shamans.
- Methodological Limitations in Research: Many published studies rely on retrospective self-selection cohorts or naturalistic designs with significant expectancy biases, demanding further double-blind, active-placebo-controlled trials to isolate non-pharmacological “set and setting” variables.
14. Related Terms & Distinctions
To avoid conceptual confusion, ayahuasca must be distinguished from several related botanical, chemical, and therapeutic constructs:
- N,N-Dimethyltryptamine (Freebase DMT): Pure DMT, when vaporized, smoked, or injected, produces an intense psychedelic experience lasting only 10 to 20 minutes, lacking the peripheral physical purge, beta-carboline synergy, and multi-hour narrative progression of ayahuasca.
- 5-MeO-DMT: Derived primarily from the secretion of the Incilius alvarius toad or synthesized chemically, 5-MeO-DMT is structurally distinct from DMT and typically produces non-visual, radical ego dissolution and oceanic consciousness rather than narrative, mythological visual imagery.
- Psilocybin: The active prodrug found in psilocybin mushrooms. While psilocybin also interacts with 5-HT2A receptors and downregulates default mode network connectivity, it is orally active without requiring metabolic MAO inhibition and possesses a distinct alkaloid profile and safety profile.
- Pharmahuasca: A synthetic pharmacological preparation combining an isolated oral MAO-A inhibitor (such as moclobemide or purified harmine) with synthetic N,N-DMT. While chemically analogous, it lacks the secondary botanical alkaloids, ritual context, and experiential trajectory characteristic of traditional whole-plant decoctions.
- Peganum harmala (Syrian Rue): A plant native to the Middle East and Central Asia containing high concentrations of harmine and harmaline, sometimes used as a substitute for Banisteriopsis caapi in non-traditional analogues (often called “Anahuasca”).
15. Summary / Key Takeaways
Ayahuasca is a sophisticated, multi-component psychoactive botanical decoction originating from indigenous Amazonian ethnomedicine. By combining beta-carboline monoamine oxidase inhibitors (derived from Banisteriopsis caapi) with the 5-HT2A agonist N,N-dimethyltryptamine (derived from admixture plants such as Psychotria viridis), the brew creates a sustained, safe-to-ingest state of modified consciousness marked by visual imagery, profound emotional processing, autobiographical insight, and structural alterations in brain network connectivity.
Contemporary empirical science indicates that ayahuasca promotes neurogenesis, reduces functional connectivity within the default mode network, and exerts promising therapeutic actions against treatment-resistant depression, substance abuse disorders, and psychological trauma. However, its use demands rigorous psychiatric screening, medical safeguards against drug-drug interactions (such as serotonin syndrome), and heightened cultural respect for its indigenous origins amidst expanding global interest.
References
- Carhart-Harris, R. L., & Friston, K. J. (2019). REBUS and the anarchic brain: Toward a unified model of the brain action of psychedelics. Pharmacological Reviews, 71(3), 316-344. https://doi.org/10.1124/pr.118.017160
- Grob, C. S., McKenna, D. J., Callaway, J. C., Brito, G. S., Neves, E. S., Oberlaender, G., Saide, O. L., Labigalini, E., Tacla, C., Miranda, C. T., Strassman, R. J., & Boone, K. B. (1996). Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil. Journal of Nervous and Mental Disease, 184(2), 86-94. https://doi.org/10.1097/00005053-199602000-00004
- McKenna, D. J. (2004). Clinical investigations of the therapeutic potential of ayahuasca: Rationale and regulatory challenges. Pharmacology & Therapeutics, 102(2), 111-129. https://doi.org/10.1016/j.pharmthera.2004.03.002
- Palhano-Fontes, F., Barreto, D., Onias, H., Andrade, K. C., Novaes, M. M., Pessoa, J. A., Mota-Rolim, S. A., Osório, F. L., Sanches, R., Dos Santos, R. G., Tofoli, L. F., de Oliveira Silveira, G., Yonamine, M., Riba, J., Santos, F. R., Silva-Junior, A. A., Alchieri, J. C., Galvão-Coelho, F. C., & de Araujo, D. B. (2019). Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: A randomized placebo-controlled trial. Psychological Medicine, 49(4), 655-663. https://doi.org/10.1017/S0033291718001356
- Riba, J., Valle, M., Urbano, G., Yritia, M., Morte, A., & Barbanoj, M. J. (2003). Human pharmacology of ayahuasca: Subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics. Journal of Pharmacology and Experimental Therapeutics, 306(1), 73-83. https://doi.org/10.1124/jpet.103.049882
- Shanon, B. (2002). The antipodes of the mind: Charting the phenomenology of the ayahuasca experience. Oxford University Press.